The Board of Pharmacy has a new look online! The redesigned website was launched in June with a clean layout and user-friendly tools for finding news and information about the board as well as links to other agencies and organizations.

The home page features new tabs to access the Consumers, Applicants, Licensees and About Us landing pages. A search box in the top right corner takes visitors to specific topics quickly. A special new feature provided by Google can now translate the full site into almost 100 different languages.

Board members Deborah Veale and Dr. Ramón Castellblanch worked with webmaster Victor Perez to develop the new design. Check it out at www.pharmacy.ca.gov.

In This Issue
Board of Pharmacy Launches Redesigned Website...Front Page
President’s Message.................................Page 2
Upcoming Board and Committee Meetings.............Page 3
Pharmacists Expanding Public Access to Naloxone......Page 4
Experts Warn Opioid Abusers Turning to Loperamide...Page 5
Notice to Consumers Available in Print, Video Formats...Page 5
Accessible Labels for Blind, Visually Impaired, Elderly.....Page 6
Valerie Muñoz Appointed to Board.......................Page 7
Ramón Castellblanch Leaves the Board....................Page 7
NABP Honors Stan Weisser for Distinguished Service....Page 7
Board Re-elects All 3 Officers..........................Page 7
Did You Know........................................Page 8
Board Honors Pharmacists Active for 50 Years..........Page 8
New Master Formula Document Requirements........Page 9
Preparing for Sterile Compounding Inspection..........Page 10
Explanation of Disciplinary Terms.......................Page 11
Disciplinary Actions....................................Page 11
Drug overdoses have become one of the leading causes of accidental death in the United States, with opioid addiction driving this epidemic. According to the CDC, over 259 million prescriptions were written for opioids in 2012 - more than enough to give every American his or her own bottle of pills.

Earlier this year, the CDC issued new prescribing guidelines for the use of opioids in chronic pain, focusing on the use of non-opioid therapy for chronic pain and promoting the use of lower opioid treatment doses to reduce risk. As pharmacists, we play an important role in promoting the safe prescribing of opioids and promoting communication to the healthcare community and our patients of the inherent risks associated with the long-term use of opioids.

One of the available tools to identify patients who may be at risk is California’s prescription drug monitoring program - CURES. The CURES system is readily available to all pharmacists who have registered, allowing for review of patient-specific prescription dispensing history for Schedule II-IV drugs from all California-licensed pharmacies. This access helps identify patients at risk and is a critical tool for pharmacists who dispense controlled substance prescriptions.

Recent legislation required that all pharmacists with active licenses apply for registration in CURES by July 1, 2016. Through statewide efforts to maximize awareness, education and active participation by pharmacists, almost 95 percent of all California licensed pharmacists were registered to access the CURES program by this past July. Not only are pharmacists registered - we are using the CURES system, with almost 500,000 patient activity reports accessed monthly by pharmacists.

Active access to CURES reports for applicable patients is encouraged for all pharmacists, as is integration of CURES report review into daily pharmacy practice. The CURES reporting process is intuitive, and information on the use of CURES is available via link from the board’s website. The board has posted a “Red Flags” video to assist pharmacists in providing appropriate review of opioid prescriptions. Every pharmacist is encouraged to watch this video and walk through the various patient vignettes presented.

Over the last few years, the board has been working to develop and implement multiple major regulations that are providing California the ability to lead the nation in promoting pharmacy practice. Much of this work is nearing completion, as highlighted below:

- The board has secured regulations creating state protocols so that pharmacists may provide nicotine replacement products and self-administered hormonal contraception to patients under their own authority. Regulations were recently approved that provide pharmacists with greater autonomy to vaccinate patients under the education and skills they have obtained as licensed pharmacists under the state protocol. In addition, the first of two advanced practice pharmacist (APP) regulations was also recently approved, paving the way for community-based pharmacist training as a route for APP qualification.

- Under final administration review are additional SB 493 regulations that allow pharmacists to provide services for travel medications and another regulation outlining qualification requirements for the new licensure category of advanced practice. Both of these are at the final stage of administration approval, with our hope that these regulations are approved and in place in the next few months.

- The board is nearing completion of its work on a major overhaul of compounding regulations for general and sterile compounding. The implementation of these regulations will represent a major effort for the board and com-

See President’s Message Page 3
Mark Your Calendar for Upcoming Board, Committee Meetings; CE Credit Available For Pharmacists, Pharmacy Technicians

Information regarding locations and agendas for all board and committee meetings is posted at the board’s website, www.pharmacy.ca.gov, at least 10 days before each meeting.

Packets of background material with information for agenda items are available for download from the website about five days before each meeting. The agenda and meeting materials are available on the board’s website.

For most meetings, pharmacists and pharmacy technicians who attend in person may be awarded six CE hours. Signing in and out on the day of the meeting will be required for CE credit.

Meetings of the California State Board of Pharmacy in 2016 are scheduled for September 22, 2016, in Southern California and October 26-27, 2016, in San Jose. Board meetings are webcast, when feasible.

Upcoming meetings of committees for 2016 are:

- Communication and Public Education Committee: December 1, 2016
- Licensing Committee: September 27, 2016

As additional meetings are scheduled, they will be posted on the board’s website. Minutes of meetings also are posted online.

President’s Message
Continued from Page 2

pounding community and hospital pharmacies.

- The board is also nearing completion of work for requirements for pharmacies to provide drug take-back services for the public, a rulemaking the board hopes to have in place by the end of 2016. This regulation relies upon the federal Drug Enforcement Administration’s drug take-back requirements and establishes parameters for collection receptacles in pharmacies, hospitals and skilled-nursing facilities as well as the use of mail-back envelopes to provide options for consumers who desire to remove unwanted medications from their homes.

- The board’s Communication and Public Education Committee recently began examining the Affordable Care Act’s requirements for pharmacy translations and interpreters for patients in 15 languages. Section 1557 of the Affordable Care Act forbids discrimination in health care because of race, color, national origin, age, disability and sex. This section of the act took effect July 18, 2016, and will likely result in impact to multiple current state pharmacy regulations.

Thank you to every stakeholder who took the time to attend a board meeting or submit public comments for the multiple pending regulations that have either been approved or are pending final approval. Your participation and voice have resulted in our ability to finalize meaningful regulations that will directly affect the provision of safe care for the consumers who rely on our pharmacies.

If you have not already done so, I encourage you to attend a board meeting and provide a voice on the future of your profession.
California pharmacists are taking a more active role in efforts to prevent deaths from opioid overdoses by increasing access to naloxone hydrochloride, a medication that reverses opioid overdose.

Authority for pharmacists to furnish naloxone was established by AB 1535 (Bloom), which was passed in 2014. The law authorized the furnishing of naloxone pursuant to a protocol developed by the Board of Pharmacy and approved by the Medical Board of California. The medication may be administered by intramuscular injection, intranasal spray or auto-injector.

The protocol, in California Code of Regulations Title 16, section 1746.3, lays out specific requirements for pharmacists to screen potential recipients and to provide training in preventing, recognizing and responding to opioid overdose and in administering naloxone. In addition, the protocol requires pharmacists to complete at least one hour of approved continuing education training on all forms of naloxone hydrochloride before furnishing the medication.

The protocol requires pharmacists to determine whether the potential recipient (A) uses illicit or prescription opioids or (B) “is in contact” with anyone who uses illicit or prescription opioids. The pharmacist also must determine whether the person to whom the drug would be administered has a known sensitivity to naloxone; if so, the pharmacist may not provide the drug.

Translated screening questions for potential recipients of naloxone whose primary language is traditional Chinese, Korean, Russian, Spanish, Tagalog or Vietnamese are available on the Board of Pharmacy website at http://www.pharmacy.ca.gov/licensees/naloxone_info.shtml.

The protocol also requires pharmacists to counsel and provide recipients with information about the medication, including “dosing, effectiveness, adverse effects, storage conditions, shelf-life, and safety.” The recipient is not permitted to waive the required consultation. The pharmacist also must provide any available information or referrals to appropriate resources to any recipient who “indicates interest in addiction treatment, recovery services, or medication disposal resources at this time.”

As members of a health care team, pharmacists may recommend that patients filling prescriptions for opioids ask their doctors to also prescribe naloxone. Alternatively, pharmacists may on their own suggest that patients filling prescriptions for opioid medications also obtain naloxone.

If the recipient is also the person to whom the naloxone would be administered, the recipient is considered a patient for purposes of the protocol. If the patient consents, section 1746.3(c)(7) requires the pharmacist to “notify the patient’s primary care provider of any drug(s) and/or device(s) furnished, or to enter the appropriate information in a patient record system shared with the primary care provider, as permitted by the patient and the primary care provider.”

If the patient does not have a primary care provider or does not consent to notification, section 1746.3(c)(7) requires the pharmacist to “provide a written record of the drug(s) and/or devices(s) furnished and advise the patient to consult an appropriate health care provider of the patient’s choice.”


A fact sheet about naloxone is available on the Board of Pharmacy website at http://www.pharmacy.ca.gov/publications/naloxone_fact_sheet.pdf.

The Board of Pharmacy Prescription Drug Abuse Prevention page, including public service announcement videos, is available at http://www.pharmacy.ca.gov/consumers/rx_abuse_prevention.shtml.
Experts Warn Opioid Abusers Are Turning To Common Anti-Diarrhea Drug Loperamide

As efforts to halt opioid abuse continue, experts warn that a growing number of people who abuse painkillers are turning to an unlikely alternative: loperamide, an anti-diarrhea medicine that is widely sold over the counter as Imodium and other brands. For some who take massive doses to ease withdrawal symptoms or get high, the results can be fatal.

A recent report in the Annals of Emergency Medicine studied two cases of substance abusers in New York who overdosed on loperamide and died. A statement issued with the report by the American College of Emergency Physicians said that loperamide is “safe in therapeutic doses but extremely dangerous in high doses.”

Researchers say the fatal overdoses in New York reflect a broader and growing trend of loperamide abuse. The American College of Emergency Physicians said the Upstate New York Poison Center had a seven-fold increase in calls regarding abuse or misuse of loperamide from 2011 to 2015. Meanwhile, national poison call centers reported a 71 percent increase in loperamide cases from 2011 to 2014.

“In June, the U.S. Food and Drug Administration warned that taking excessive amounts of loperamide can cause serious problems with heart rhythm and lead to death. Out of 48 cases of serious heart problems associated with loperamide that the FDA received between 1976 and 2015, more than half were reported after 2010.

Although the active ingredient in loperamide is an opioid, the medication has been approved by the FDA since 1976 to help control diarrhea. The maximum approved daily dose is 8 milligrams for over-the-counter use and 16 milligrams for prescription use.

But in a 2012 study of almost 1,300 loperamide abusers who posted in online forums, some reported taking 70 to 100 milligrams a day. Seventy percent reported taking “megadoses” to alleviate opioid withdrawal symptoms, while 25 percent said they did so in an effort to produce euphoria.

“Loperamide’s accessibility, low cost, over-the-counter legal status and lack of social stigma all contribute to its potential for abuse,” said William Eggleston, a doctor of pharmacy and lead author of the Annals of Emergency Medicine study.

“Our nation’s growing population of opioid-addicted patients is seeking alternative drug sources with prescription opioid medication abuse being limited by new legislation and regulations,” Dr. Eggleston said. “Health care providers must be aware of increasing loperamide abuse and its under-recognized cardiac toxicity. This is another reminder that all drugs, including those sold without a prescription, can be dangerous when not used as directed.”

“Notice to Consumers” Available in Various Formats

California Code of Regulations section 1707.6 requires pharmacies to display a Notice to Consumers as specified in subsection (b). Full-size posters in English and Spanish are available to be ordered at the board’s website. Smaller versions Chinese, Korean, Russian, Spanish, Tagalog and Vietnamese may be printed or ordered at the board’s website.

As an alternative to a printed format, Section 1707.6 allows pharmacies to display the Notice to Consumers on a video screen. The Notice to Consumers is available in video format in English and Spanish at the Board of Pharmacy’s website under “Publications for Applicants and Licensees.” Both versions can be downloaded as PowerPoint presentations.

A pharmacy also may seek approval of another format or display methodology from the Board of Pharmacy’s Executive Officer.

Section 1707.6 (a)(1)-(4) lists specific requirements for displaying the Notice to Consumers on a video screen instead of in printed form. The section requires:

(1) The video screen is at least 24 inches, measured diagonally;

(2) The pharmacy utilizes the video image notice provided by the Board of Pharmacy;

(3) The text of the notice remains on the screen for a minimum of 60 seconds; and

(4) No more than five minutes elapses between displays of any notice on the screen, as measured between the time that a one-screen notice or the final screen of a multi-screen notice ceases to display and the time that the first or only page of that notice re-displays.
Federal Group Recommends Best Practices For Making Prescription Drug Labels Accessible To Blind, Visually Impaired, Elderly Patients

Federal best practices for prescription drug containers have been developed to make it easier for people who are blind, visually impaired or elderly to access label information.

The recommended best practices were developed by a working group of consumer and drug industry advocates convened by the United States Access Board under the Food and Drug Administration Safety and Innovation Act (Public Law 112-144, 126 Stat. 993).

The working group stated that people who cannot read printed prescription labels because of visual impairment “all too often take the wrong medication, the wrong amount, at the wrong time and under the wrong instructions.” The group also noted that most people who become blind or visually impaired do so after age 60 – a time when many take multiple medications and have physical and cognitive conditions that increase the need for “safe, consistent, reliable and independent access” to drug label information.

Recommendations of the federal working group include:

- Encourage patients to communicate their needs to pharmacists.
- Follow universal patient-centered prescription drug container label standards.
- Make container labels available in audible, braille and large-print formats. Explain the choices and provide the format selected by the patient.
- Ensure that duplicate accessible labels preserve the integrity of the print prescription label.
- Subject accessible prescription labels to the same quality control processes used for print labels to ensure accuracy and patient safety.
- Maintain patient privacy (HIPPA rules) when preparing accessible drug labels.
- Keep a sufficient inventory of supplies to provide accessible labels.
- Provide drugs with an accessible label within the same time frame as would be provided to patients without visual impairments.
- Don’t impose an extra fee to cover the cost of providing an accessible drug label.
- Ensure durability of accessible label formats until the prescription expiration date.
- Select a container that best supports the type of accessible label provided.
- Ensure all required information contained on the print prescription drug label is provided in the same sequence on the accessible label.
- Include in accessible labels the information on warning labels added to the container at the pharmacist’s discretion.

A variety of methods and technologies exist to enable blind, visually impaired and elderly people to access information on prescription labels, including:

- Hard copy labels printed in large type or braille.
- Digital voice or text-to-speech recorders – “Talking bottles” that use a small electronic device attached to a drug container to read the label information aloud.
- Radio Frequency Identification Device (RFID) tags – Attaching RFID tags to drug containers that enable a dedicated device used by the patient to read the label aloud.
- Smart devices and computers equipped with electronic braille, large text and audio technology to access electronic text.

A brochure listing the best practices was issued in June 2016 by the National Council on Disability. The brochure is available at http://www.ncd.gov/sites/default/files/ADLP_508.pdf.

Additional information about the recommended best practices and a link to the working group’s full report is available at https://www.access-board.gov/guidelines-and-standards/health-care/about-prescription-drug-container-labels.
Valerie Muñoz Appointed to Board

Valerie Muñoz of La Puente was appointed in July as a public member of the Board of Pharmacy by the Senate Rules Committee.

Ms. Muñoz is mayor of La Puente and has served on the City Council since 2014. She is a delegate to the California Contract Cities Association and an alternate to the League of California Cities and the Foothill Transit Authority board.

She works as a practice and human resources manager for an optometry business. She earned a master’s degree in leadership and organizational studies and a bachelor’s degree in organizational studies from Azusa Pacific University.

Ramón Castellblanch Leaves After 2 Terms as Public Member

Board of Pharmacy member Ramón Castellblanch, Ph.D., is leaving after two terms as a public member of the board.

Dr. Castellblanch was appointed to the board by the Senate Rules Committee in 2009 and was reappointed in 2012. He served most recently on board’s Communication and Public Education Committee and the Legislation and Regulation Committee. Dr. Castellblanch previously served as the Chairperson on the Prescription Drug Abuse Subcommittee. Dr. Castellblanch was a supporter of patient-centered prescription labels, translation and interpreter services for pharmacy patients, prescription drug abuse awareness and education as well as consumer health education.

NABP Honors Stanley C. Weisser With Top Award for Distinguished Service

The National Association of Boards of Pharmacy (NABP) has presented its highest honor, the Lester E. Hosto Distinguished Service Award, to California State Board of Pharmacy Member Stanley C. Weisser.

Mr. Weisser was honored for “his strong commitment to protecting the public health and his successful advancement of higher standards and stronger oversight for sterile compounding pharmacies,” the NABP said in a written statement. The award was presented at the NABP’s 112th Annual Meeting May 14-17, 2016, in San Diego.

A member of the California State Board of Pharmacy since 2007, Mr. Weisser served as president from 2010 to 2015. As chairman of the SB 493 Implementation Committee, he led efforts to specify requirements for licensing advanced practice pharmacists in California and to develop three state protocols and two additional regulations to implement extended care requirements. He is an associate clinical professor at Loma Linda University School of Pharmacy and serves on the executive committee of Redlands Community Hospital and the Board of Trustees of University of Redlands.

The Lester B. Hosto Distinguished Service Award recognizes individuals whose efforts to protect the public health greatly further the goals and objectives of the NABP. The award is named in memory of former NABP President Lester E. Hosto, whose contributions to the pharmacy practice were recognized by practitioners in his state, pharmacy leaders across the nation and former U.S. President Bill Clinton.

Board Re-elects All 3 Officers

Board of Pharmacy President Amy Gutierrez, Vice President Deborah Veale and Treasurer Victor Law were re-elected as officers at a board meeting on April 27.

Dr. Gutierrez joined the board in 2012. She worked at the Los Angeles County Department of Health Services since 1984 and has served as chief pharmacy officer and director of pharmacy since 2006. Dr. Gutierrez earned a doctorate in pharmacy from the University of Southern California, School of Pharmacy.

Ms. Veale has served on the board since 2010. She has been director of payer relations for CVS Pharmacy since 2006 and previously served in several positions with Albertsons/Sav-On Drugs. She earned a pharmacy degree from the University of Iowa, College of Pharmacy.

Mr. Law has been a board member since 2012. He has served as chief pharmacist and president at Alpha Medical Pharmacy Inc. since 1987. He earned a bachelor’s degree in pharmacy from the University of Oklahoma in 1976.
Almost six of every 10 licensed pharmacists in California are women. According to the California State Board of Pharmacy, 58 percent of the 35,526 registered pharmacists with California addresses on file are women, compared with 42 percent who are men.

The California numbers reflect a national trend. A 2014 National Pharmacist Workforce Study issued by the American Association of Colleges of Pharmacy reported that women made up 57.1 percent of actively practicing pharmacists in the United States.

In addition, female pharmacists in California are mostly younger than their male colleagues. More than half – 51 percent – of licensed female pharmacists who are California residents are between the ages of 30 and 44. Meanwhile, 53 percent of licensed male pharmacists who live in the state are 50 or older.

As of June 15, 2016, a total of 41,586 pharmacists were licensed by the Board of Pharmacy with active licenses. The total includes 5,947 pharmacists with addresses in other states and an additional 113 with addresses outside the United States.

The Board of Pharmacy pays tribute to those who have been registered California pharmacists on active status for at least 50 years. The board recognizes these individuals and gratefully acknowledges their years of contribution to the pharmacy profession. These pharmacists may take great pride in being part of such an honorable profession for so long.

Pharmacists who recently received a certificate commemorating 50 years of service and were invited to attend Board meetings to be publicly honored are:

- Freeman, Lary E.
- Blair, William J.
- Chaplain, Raymond Miles
- Gerome, Norman Louis
- Heincy, Charles Daniel
- Hill, Archie Richard
- Horowitz, Kenneth N.
- Hutchison, Loyal Dwayne
- Lyons, Noel E.
- Mariottini, Raymond E.
- Marotto, Ronald Raymond
- Petroni, Frank Gary
- Siu, Kienki
- Siu, Kingmun
- Sudalter, Lawrence
- Taj, Patricia Kawase
- Zingarelli, Robert N.

Incline Village, NV
Santa Ana, CA
San Clemente, CA
Calabasas, CA
Granite Bay, CA
Santa Rosa, CA
Hermosa Beach, CA
Stockton, CA
Chico, CA
Hollister, CA
Goleta, CA
Atascadero, CA
Fort Jones, CA
Alameda, CA
Santa Clara, CA
San Ramon, CA
Fresno, CA

The following pharmacists were honored for being licensed for 50 years at a previous Board meeting:

- Phillip E. Grauss
- Loyal D. Hutchison
- Kingman Siu
New Compounding Regulation Will Change Elements For Master Formula Documents

A master formula document is the specific recipe written by a pharmacy before it compounds a preparation. The requirements for a master formula will change on 1/1/17, pending approval of the board’s compounding regulations.

Assuming the regulations are adopted, the required elements of the master formula will change and must appear in a cohesive document. As with prior regulations, the master formula must be prepared before compounding begins.

As proposed, California Code of Regulations, Title 16, section 1735.2, subsection (e), will require:

A drug preparation shall not be compounded until the pharmacy has first prepared a written master formula document that includes at least the following elements:

(1) Active ingredients to be used.

(2) Equipment to be used.

(3) The maximum allowable beyond use date (BUD) for the preparation, and the rationale or reference source justifying its determination.

(4) Inactive ingredients to be used.

(5) Specific and essential compounding steps used to prepare the drug.

(6) Quality reviews required at each step in preparation of the drug.

(7) Post-compounding process or procedures required, if any.

(8) Instructions for storage and handling of the compounded drug preparation.

Here are some examples of what you might expect the master formula document to provide for each of the above elements:

(1) Active ingredients to be used – For example, we might expect to see the active product(s), active pharmaceutical ingredient(s) (API), or active bulk substance.

(2) Equipment to be used – For example, the master formula document might reflect the hood(s), repeater pumps, scales or other equipment.

(3) The maximum allowable beyond use date (BUD) for the preparation, and the rationale or reference source justifying its determination – For example, the rationale or reference source justifying how the BUD is determined might include:

- For a compounded preparation – stability studies.

- For a compounded sterile preparation – method suitability test, container closure integrity tests, and/or stability studies and/or sterility study.

(4) Inactive ingredients to be used – For example, the master formula document might reflect the inactive product(s) or bulk substance(s) included in the preparation: for example, normal saline (NS), 5% dextrose in normal saline (D5W).

(5) Specific and essential compounding steps used to prepare the drug – For example, the master formula document might reflect a narrative of the physical processes: which ingredients, in what form, what strengths/volumes are mixed first, under what circumstances, held under what conditions for how long, in what environment, etc.

(6) Quality reviews required at each step in preparation of the drug – We might expect to see a description of each quality review in each specific and essential compounding step. For example, the master formula document might reflect that compounding staff will:

- Check that all powder is in the solution for a reconstituted product.

- Check that no powder/liquid left the neck of the vial or ampule.

- Check for correct coloring.

See Master Formula Documents Page 10
Master Formula Documents

Continued from Page 9

- Check for coring of the stopper.
- Check for precipitates.
- Check for leaks.

(7) Post-compounding process or procedures required, if any – For example, the master formula document might reflect that compounding staff will:

- Place [specified ingredient or preparation] in a defined quarantine area.
- Send [X] number of samples out for sterility and endotoxin testing.
- Review of sterility and endotoxin results for satisfactory values.
- Conduct a filter integrity test on all filters used.

(8) Instructions for storage and handling of the compounded drug preparation – We would expect to see what conditions the compound drug preparations should be held under for how long. For example: protect from light, refrigerate, discard 24 hours after opened.

Have Records Ready for Compounding Inspections

Licensed sterile compounding pharmacies should have certain items immediately available for inspection by Board of Pharmacy inspectors. If any documents are electronically maintained, they must be readily retrievable by all staff and available upon request.

The board suggests that an inspection binder be created that contains the following items:

1. Most recent Self-Assessments for both the pharmacy (PHY, PHE, HSP, HPE, etc.) and each sterile compounding permit within the location (LSC, LSE, NSC, etc.)
2. Most recent State Board inspections (CA and other for non-resident pharmacies, if applicable)
3. Any FDA, DEA or accreditation inspections with applicable reports or warning letters
4. Compounding policies and procedures (P&Ps, SOPs, etc.)
5. Documentation that all new policies and procedures (or lack thereof) within the last 12 months have been reported to the Board
6. Master Formula Documents
7. Completed recent patient-specific compounding records with associated label(s)
8. Compounding area semi-annual or annual (as applicable) certification reports
9. QA policies and procedures with documentation (reports) of end product testing (qualitative and quantitative analysis)
10. Non-sterile to sterile compounded product testing documentation (certificate of analysis (CoA))
11. Certificates of analysis for non-sterile components used in compounding for all ISO certified spaces
12. Records of initial training for compounding staff
13. Records of annual competencies for compounding staff
14. Records of the environmental sampling conducted in the pharmacy
15. Daily/Weekly/Monthly Cleaning logs
16. Temperature logs (refrigerator, freezer, incubator, etc., as applicable)
17. Humidity and pressure logs
18. Sample labels
### Explanation of Disciplinary Terms

**Accusation Filed**—an accusation is the document containing the charges and allegations of violations of the law filed when an agency is seeking to discipline a license.

**Effective Date of Action**—the date the disciplinary action goes into operation.

**Revocation or Revoked**—the license is revoked as a result of disciplinary action by the Board, and the licensee’s right to practice or operate a Board-licensed entity is ended.

**Revoked, Stayed**—the license is revoked, but the revocation is postponed until the Board determines whether the licensee has failed to comply with specific probationary conditions, which may include suspension of the licensee’s right to practice.

**Stipulated Settlement**—the board and a licensee mutually agree to settle a disciplinary case brought by the board by way of a settlement agreement.

**Stayed**—the revocation or suspension action is postponed, and operation or practice may continue so long as the licensee fully complies with any specified terms and conditions.

**Probation**—the licensee may continue to practice or operate a Board-licensed entity under specific terms and conditions for a specific period of time.

**Voluntary Surrender**—the licensee has agreed to surrender his or her license, and the right to practice or operate Board-licensed entity is ended. The board may agree to accept the surrender of a license through a “stipulation” or agreement.

**Suspension**—the licensee is prohibited from practicing or operating a Board-licensed entity for a specific period of time.

**Suspension/Probation**—the licensee is prohibited from practicing or operating a Board-licensed entity for a specific period of time, and the right to practice or operate is contingent upon meeting specific terms and conditions during the probationary period.

**PC 23 Order Issued**—the licensee is restricted from practicing or operating a Board-licensed entity by a court order that is issued under the provisions of Penal Code section 23.

**Public Reprimand**—resulting from a disciplinary action, the licensee is issued a letter of public reprimand.

**Reinstatement of License**—a previously revoked or suspended license is reinstated with or without specified terms and conditions.

**Statement of Issues**—a legal document that details the factual or legal basis for refusing to grant or issue a license.

### Disciplinary Actions

**APRIL 1, 2016 - JUNE 30, 2016**

**Personal Licenses**

**Designated Representative**

Barajas, Raul J., EXC 18131, Administrative Case AC 4577
San Diego, CA
Through a disciplinary action of the Board, the license is revoked, canceled and the right to practice or operate has ended.
Decision effective 5/12/2016.
View the decision

**Pharmacy Technicians**

Pogosyan, Khachatur, EXC 19398, Administrative Case AC 5244
Burbank, CA
Through a disciplinary action of the Board, the license is voluntarily surrendered.
Decision effective 5/6/2016.
View the decision

Pogosyan, Khachatur, EXC 19398, Administrative Case AC 4802
Burbank, CA
Through a disciplinary action of the Board, the license is voluntarily surrendered.
Decision effective 5/6/2016.
View the decision

Alarcon, Juan Luis, TCH 82087, Administrative Case AC 4870
Lynwood, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on
Brito, Gina, TCH 115393, Administrative Case AC 5544 Palmdale, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 6/06/2016.
View the decision

Chagolla, Johnny A., TCH 62803, Administrative Case AC 5171 Riverside, CA
Through a disciplinary action of the Board, the license is revoked, revocation stayed, and placed on probation for 3 years subject to the terms and conditions in the decision.
Decision effective 4/6/2016.
View the decision

Clark, Debbie, Applicant, Statement of Issues Case SI 5243 Palmdale, CA
Through a disciplinary action of the Board, the Application for Registration as a Pharmacy Technician is granted. Upon satisfaction of all statutory and regulatory requirements, the license is issued, immediately revoked, the revocation stayed, and respondent is placed on probation for 5 years subject to the terms and conditions in the decision.
Decision effective 4/1/2016.
View the decision

Coon, Susan Renee, TCH 104205, Administrative Case AC 5018 Bakersfield, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 5/26/2016.
View the decision

Crawford, Steven Michael, TCH 75843, Administrative Case AC 5582 Arcadia, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 5/26/2016.
View the decision

Cusic, Crystal Nichole, TCH 110409, Administrative Case AC 5602 Sacramento, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Avetisyan, Anush Ana, TCH 106798, Administrative Case AC 5635 North Hollywood, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 4/1/2016.
View the decision

Bradford, Cedell, TCH 62355, Administrative Case AC 5376 Oakland, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for five years, and is subject to the terms and conditions in the decision.
Decision effective 6/06/2016.
View the decision

Bridges, Jennifer Ann, TCH 60386, Administrative Case AC 5234 Citrus Heights, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 4/04/2016.
View the decision

Donaldson, Pamela, TCH 22260, Administrative Case AC 5357 Temecula, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Ellison, Lori Lee, TCH 41237, Administrative Case AC 5486 Bakersfield, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 5/6/2016.
View the decision

Evardome, Heather, TCH 13938, Administrative Case AC 5239 Glendora, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Garcia, Linda, TCH 49093, Administrative Case AC 5197 Sylmar, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 6/06/2016.
View the decision

See Disciplinary Actions, Page 13
Disciplinary Actions
Continued from Page 18

Geddes, Janet, TCH 7916, Administrative Case AC 5711
Anaheim, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Guillen, Evelyn Lissette, TCH 138520, Administrative Case AC 5450
Long Beach, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Hasenberg, Lisa Ann, TCH 77620, Administrative Case AC 5608
Carlsbad, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 4/1/2016.
View the decision

Hernandez, Angela, TCH 61795, Administrative Case AC 5334
Downey, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Johnson, Lonzo Leroy, Applicant, Statement of Issues Case SI 5652
Riverside, CA
Through a disciplinary action of the Board, the Pharmacy Technician Application is granted. Upon satisfaction of all statutory and regulatory requirements, the license is issued, immediately revoked, the revocation stayed, and respondent is placed on probation for 5 years subject to the terms and conditions in the decision.
View the decision

Learn, Daniel James, TCH 42139, Administrative Case AC 5650
Murrieta, CA
Through a disciplinary action of the Board, the license is voluntarily surrendered.
Decision effective 6/6/2016.
View the decision

Lopez, Mychael, TCH 131980, Administrative Case AC 5458
Norwalk, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 6/6/2016.
View the decision

Lossner, Daniel Aaron, TCH 88530, Administrative Case AC 5432
Grass Valley, CA
Through a disciplinary action of the Board, the license is voluntarily surrendered.
Decision effective 4/1/2016.
View the decision

Lucero, Milton, TCH 108177, Administrative Case AC 5410
Antioch, CA
The accusation is withdrawn.
Decision effective 4/6/2016.
View the decision

Mejia, Daniel, TCH 109456, Administrative Case AC 5374
Bellflower, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 5/26/2016.
View the decision

Montes, Julio Cesar, TCH 129392, Administrative Case AC 5616
Santa Ana, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 4/1/2016.
View the decision

Murphy, Daniel Jean-Paul, TCH 72306, Administrative Case AC 5625
Murrieta, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

O’Leary, Casey M., TCH 104680, Administrative Case AC 5312
Victorville, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Ortega, Richard, Applicant, Statement of Issues Case SI 5383
Fontana, CA
Through a hearing decision adopted by the Board, the Application for Registration as Pharmacy Technician is denied.
Decision effective 6/6/2016.
View the decision

Pal, William Rajan, TCH 108853, Administrative Case AC 5395
Antelope, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 5/6/2016.
View the decision

Rodriguez, Enrique, TCH 72559, Administrative Case AC 5297
San Lorenzo, CA
Through a disciplinary action of the Board, the license is revoked, revocation stayed, and placed on probation for 4 years subject to the terms and conditions in the decision.
View the decision

Soliz, Mika, TCH 24839, Administrative Case AC 4935
Redlands, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

See Disciplinary Actions, Page 14
Disciplinary Actions
Continued from Page 19

probation for three years subject to the terms and conditions in the decision.
View the decision

Solorio, Sylvia Theresa, TCH 79018, Administrative Case AC 5600
Pico Rivera, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 4/1/2016.
View the decision

Song, Bridgett Vicharra, TCH 131914, Administrative Case AC 5445
Long Beach, CA
Through a disciplinary action of the board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Spencer Jr., Dean Russell, TCH 100459, Administrative Case AC 5618
Napa, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Streetman, Heather Rose, TCH 111247, Administrative Case AC 5479
Auburn, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 5/26/2016.
View the decision

Vasquez, Justin Andrew, TCH 124217, Administrative Case AC 5648
Victorville, CA
Through a disciplinary action of the board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Wentworth, Sarah, TCH 106086, Administrative Case AC 5649
Redding, CA

Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Williams, Katherine, TCH 32771, Administrative Case AC 5575
Pittsburg, CA
Through a disciplinary action of the Board, the license is voluntarily surrendered.
View the decision

Intern Pharmacists

Hamouda, Kamal Elsayed Ahmed, Applicant, Statement of Issues Case SI 5500
Palmdale, CA
Through a hearing decision adopted by the Board, the Application for Registration as an Intern Pharmacist is denied.
Decision effective 4/20/2016
View the decision

Ismail, Mohamed Sayed Hafez, INT 33563, Administrative Case 5721
Bakersfield, CA
View the decision

Oh, Daniel Young, INT 29660, Administrative Case AC 5477
Irvine, CA
Through a disciplinary action of the Board, the license is voluntarily surrendered.
View the decision

Pharmacists

Amin, Pradeep Kumar, RPH 40574, Administrative Case AC 4826
San Bernardino, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for 5 years and is subject to the terms and conditions in the decision, including a 20-day suspension.
Decision effective 4/1/2016.
View the decision

Avedissian, Mike, RPH 43996, Administrative Case AC 4913
Burbank, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for 5 years and is subject to the terms and conditions in the decision, including a one year suspension.
Decision effective 4/1/2016.
View the decision

Carroll, Andrew Paul, RPH 60030, Administrative Case AC 5216
Redlands, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for 5 years, and is subject to the terms and conditions in the decision, including suspension until deemed safe to practice.
Decision effective 6/30/2016.
View the decision

Chan, Johnny Pinghon, RPH 32261, Administrative Case AC 5113
Hillsborough, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Clark, Emily Anne, RPH 63443, Administrative Case AC 5179
Visalia, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
View the decision

Fullmer, Wade Leslie, RPH 28731, Administrative Case AC 5542
Turlock, CA
Through a disciplinary action of the Board, the license is voluntarily surrendered.
Decision effective 5/26/2016.
View the decision
Disciplinary Actions
Continued from Page 20

Gillung, Harold Eugene, Applicant, Statement of Issues Case SI 5540
San Diego, CA
Through a disciplinary action of the Board, the Application for Pharmacist Examination and Licensure is granted. Upon satisfaction of all statutory and regulatory requirements for the issuance of a pharmacist license, the license shall be issued and immediately revoked, the revocation will be stayed and the license will be placed on probation for 5 years subject to the terms and conditions in the decision.
Decision effective 6/06/2016.
View the decision

Grasela, Joseph, RPH 40868, Administrative Case AC 4347
San Diego, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for 4 years, and is subject to the terms and conditions in the decision.
Decision effective 4/1/2016.
View the decision

Ho, Christopher, Tri, RPH 55450, Administrative Case AC 5299
Huntington Beach, CA
Through a disciplinary action of the Board, the license is subject to a Letter of Public Reproval.
Decision effective 5/12/2016.
View the decision

Huynh, Khoa Tan, RPH 56097, Administrative Case AC 5283
Clovis, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for three years, and is subject to the terms and conditions in the decision.
Decision effective 6/06/2016.
View the decision

Ismaeil, Mohamed Sayed Hafez, Pharmacist Applicant, Statement of Issues Case 5721
Bakersfield, CA
View the decision

Kears, Chad, RPH 42817, Administrative Case AC 5267
Newport Beach, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for 5 years, and is subject to the terms and conditions in the decision.
Decision effective 5/26/2016.
View the decision

Le, Viet Du, Applicant, Statement of Issues Case SI 5472
Garden Grove, CA
Through a disciplinary action of the Board, the Application for Pharmacist Examination and Licensure is granted. Upon satisfaction of all statutory and regulatory requirements, the license is issued, immediately revoked, the revocation stayed, and respondent is placed on probation for 5 years subject to the terms and conditions in the decision.
Decision effective 4/1/2016.
View the decision

Lee, Victor, Applicant, Statement of Issues Case SI 5460
Cerritos, CA
Through a disciplinary action of the Board, the Application for Pharmacist Examination and Licensure is granted. Upon satisfaction of all statutory and regulatory requirements, the license will be issued, immediately revoked, the revocation will be stayed, and respondent will be placed on probation for 5 years subject to the terms and conditions in the decision.
Decision effective 5/12/2016.
View the decision

Madievsky, Dana, RPH 48684, Administrative Case AC 5059
Studio City, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for five years, and is subject to the terms and conditions in the decision.
Decision effective 5/12/2016.
View the decision

Nguyen, Hugh Quochuy, RPH 62556, Administrative Case AC 5405
Pasadena, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 5/26/16.
View the decision

Oh, Daniel Young, Applicant, Statement of Issues Case SI 5478
Irvine, CA
Through a disciplinary action of the Board, the Application for Pharmacist Examination and Licensure is granted. Upon satisfaction of all statutory and regulatory requirements, the license shall be issued, immediately revoked, the revocation stayed, and respondent is placed on probation for 5 years subject to the terms and conditions in the decision.
View the decision

Panab, Lisa Anne, RPH 47276, Administrative Case AC 4493
Scotts Valley, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for five years, and is subject to the terms and conditions in the decision, including a 10-day suspension.
Decision effective 6/06/2016.
View the decision

Peters, Harry, RPH 28331, Administrative Case AC 5106
Los Angeles, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective 4/13/2016.
View the decision

See Disciplinary Actions, Page 16
## Disciplinary Actions

*Continued from Page 21*

Stange, Stephen L., RPH 28242, Administrative Case AC 5294
Stockton, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for five years, and is subject to the terms and conditions in the decision.
Decision effective 6/06/2016.
View the decision

Ta, Jamie Trang, RPH 59312, Administrative Case AC 5283
Clovis, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for three years, and is subject to the terms and conditions in the decision.
Decision effective 6/06/2016.
View the decision

Tran, Vinh Le, RPH 59831, Administrative Case AC 5295
Huntington Beach, CA
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for five years, and is subject to the terms and conditions in the decision.
Decision effective 5/12/2016.
View the decision

Youssef, Ali Hussein, RPH 64023, Administrative Case AC 5122
Granada Hills, CA
Through a disciplinary action of the Board, the license is revoked and canceled and the right to practice or operate has ended.
Decision effective date 5/23/2016.
View the decision

Yuen, James Po Kwong, RPH 43557, Administrative Case AC 5010
Walnut Creek, CA
Through a disciplinary action of the board, the license is voluntarily surrendered.
Decision effective 4/20/2016.
View the decision

## Facility Licenses

### Sites

<table>
<thead>
<tr>
<th>Facility Name</th>
<th>Location</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Advance Medical Pharmacy, PHY 46345</td>
<td>Walnut Creek, CA</td>
<td>Through a disciplinary action of the Board, the license is voluntarily surrendered, however, the surrender is stayed until May 1, 2016, at which time the pharmacy shall be sold or closed. Decision effective 4/20/2016. View the decision</td>
</tr>
<tr>
<td>Corona Del Mar, CA</td>
<td>Through a disciplinary action of the Board, the license is voluntarily surrendered. Decision effective 5/26/2016. View the decision</td>
<td></td>
</tr>
<tr>
<td>CVS Pharmacy No. 5837, PHY 46780</td>
<td>Buena Park, CA</td>
<td>Through a disciplinary action of the Board, the license is subject to a Letter of Public Repraval. Decision effective 5/12/2016. View the decision</td>
</tr>
<tr>
<td>Dubin Medical, Inc., Applicant, Statement of Issues Case SI 5494</td>
<td>West Valley, UT</td>
<td>Through a disciplinary action of the Board, the Application for a Non-Resident Wholesaler License is granted. Upon satisfaction of all statutory and regulatory requirements, the license will be issued, immediately revoked, the revocation will be stayed, and respondent will be placed on probation for 5 years subject to the terms and conditions in the decision. Decision effective 5/12/2016. View the decision</td>
</tr>
<tr>
<td>Dubin Medical, Inc., WLS 6797</td>
<td>San Diego, CA</td>
<td>Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the license is placed on probation for three years, and is subject to the terms and conditions in the decision. Decision effective 5/26/2016. View the decision</td>
</tr>
</tbody>
</table>

See Disciplinary Actions, Page 17
Disciplinary Actions  
Continued from Page 22

Pharma-RX Inc., WLS 5405, Administrative Case AC 5405 Glendale, CA  
Through a disciplinary action of the Board, the license is voluntarily surrendered.  
Decision effective 5/6/2016.  
View the decision

Script Life Pharmacy, PHY 50069, Administrative Case AC 5283 Clovis, CA  
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for three years, and is subject to the terms and conditions in the decision.  
Decision effective 6/06/2016.  
View the decision

Sierra Pharmacy, PHY 49260, Administrative Case AC 4826 San Bernardino, CA  
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for 4 years and is subject to the terms and conditions in the decision including a seven day suspension from pharmacy operations beginning May 2, 2016 through May 9, 2016.  
Decision effective 4/1/2016.  
View the decision

TBT Pharmacy, Inc., PHY 50904, Administrative Case AC 5295 Huntington Beach, CA  
Through a disciplinary action of the Board, the license is voluntarily surrendered.  
Decision effective 5/12/2016.  
View the decision

University Compounding Pharmacy, PHY 45621, Administrative Case AC 4347 San Diego, CA  
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for 4 years and is subject to the terms and conditions in the decision.  
Decision effective 4/1/2016.  
View the decision

University Compounding Pharmacy, LSC 99018, Administrative Case AC 4347 San Diego, CA  
Through a disciplinary action of the Board, the license is revoked, the revocation is stayed, and the licensee is placed on probation for 4 years and is subject to the terms and conditions in the decision.  
Decision effective 4/1/2016.  
View the decision